SPARC.NS - Sun Pharma Advanced Research Company Limited

NSE - NSE Real Time Price. Currency in INR

Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Centre
Akota Road
Vadodara 390020
India
91 26 5233 0815
http://www.sunpharma.in

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees398

Key Executives

NameTitlePayExercisedAge
Mr. Dilip Shantilal ShanghviN/AN/A62
Mr. Chetan Rajpara1.72MN/AN/A
Mr. Debashis Dey2.43MN/AN/A
Mr. Anil RaghavanN/AN/AN/A
Dr. Subhas BhowmickN/AN/A61
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Sun Pharma Advanced Research Company Limited operates as a pharma research and drug discovery company in India and internationally. It develops new chemical entities and products based on its proprietary novel drug delivery systems. The company’s core therapeutic areas of interest include oncology, inflammation, and neurodegenerative diseases, as well as developing abuse deterrent formulations. It offers Levetiracetam ER for epilepsy. The company is also developing Latanoprost BAK free eye drops for glaucoma; Baclofen gastric retention systems for spasticity; salmeterol-fluticasone DPI for asthma/COPD; paclitaxel injection concentrates for nanodispersion for the treatment of cancer; SUN-K706 and SUN-K095 for chronic myelogenous leukemia; and Brimonidine OD for glaucoma. In addition, it is developing SDN-021 and Tizanidine ER for pain; SUN-597 Topical for atopic dermatitis; minocycline topical for acne; and octreotide LAR for acromegaly. The company was incorporated in 2006 and is based in Vadodara, India. As of March 30, 2017, Sun Pharma Advanced Research Company Limited operates as a subsidiary of Shanghvi Finance Pvt. Ltd.

Corporate Governance

Sun Pharma Advanced Research Company Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.